BIO-TECHNE earnings release, August 12, 2026

BIO-TECHNE Corp (TECH) · Form 8-K, Item 2.02 · Filed · SEC filing

​

Bio-Techne Releases Fourth Quarter Fiscal 2026 Results

​

Minneapolis/August 12, 2026/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2026.

​

Fourth Quarter FY2026 Highlights

​

● Fourth quarter organic revenue increased by 3% (1% reported) to $321.2 million. Full year organic and reported revenue remained flat at $1.2 billion.

​

● GAAP EPS increased to $0.35 from $(0.11) one year ago. Delivered adjusted EPS was $0.52, down from $0.53 one year ago. Full year GAAP EPS increased to $1.16 versus $0.46 one year ago. Full year adjusted EPS was $1.93, up from $1.92 one year ago.

​

● As previously announced on June 25, 2026, Bio-Techne entered into an agreement to be acquired by Merck KGaA, Darmstadt, Germany for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion.

​

“Bio-Techne ended fiscal 2026 with improved performance and solid execution across the business, reflecting the value our differentiated solutions bring across biopharma, research and diagnostic workflows,” said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. “We continue to make progress toward completing Bio-Techne’s acquisition by Merck KGaA, Darmstadt, Germany, and look forward to the opportunities this transaction is expected to create for our customers and employees.”

​

Conference Call

​

In light of the announced transaction with Merck KGaA, Darmstadt, Germany, Bio-Techne is no longer holding investor conference calls for quarterly results.

​

Fourth Quarter Fiscal 2026

​

Revenue

​

Net sales for the fourth quarter increased 1% to $321.2 million. Organic growth increased 3% compared to the prior year. Non-recurring prior year revenue from a business held-for-sale had an unfavorable impact of 2% and foreign currency exchange did not have a material impact.

​

GAAP Earnings Results

​

GAAP EPS was $0.35 per diluted share versus $(0.11) in the same quarter last year. GAAP operating income for the fourth quarter of fiscal 2026 was

$74.3 million compared to an operating loss of $23.9 million in the fourth quarter of fiscal 2025. GAAP operating margin was 23.1% compared to (7.5)% in the fourth quarter of fiscal 2025. Current quarter GAAP operating margin was favorably impacted by a non-recurring impairment charge in the prior year.

​

Non-GAAP Earnings Results

​

Adjusted EPS decreased to $0.52 per diluted share compared to $0.53 in the same quarter last year. Adjusted operating income increased to $103.4 million in the fourth quarter of fiscal 2026 compared to $101.3 million in the fourth quarter of fiscal 2025. Adjusted operating margin was 32.2% for the fourth quarter of fiscal 2026 compared to 32.0% in the fourth quarter of fiscal 2025. Adjusted operating margin was favorably impacted by profitability initiatives and the Exosome Diagnostics divestiture, partially offset by unfavorable product mix.

​

Full Year Fiscal 2026

​

Revenue

​

Net sales for the full year fiscal 2026 remained flat from the prior year at $1.2 billion. Organic revenue remained flat from the prior year. Foreign currency exchange had a favorable impact of 2% and a business held-for-sale had an unfavorable impact of 2%.

​

GAAP Earnings Results

​

GAAP EPS was $1.16 per diluted share, compared to $0.46 last fiscal year. GAAP operating income for full year fiscal 2026 increased 146% to $251.9 million, compared to $102.3 million in the full year fiscal 2025. GAAP operating margin was 20.7% compared to 8.4% in the full year fiscal 2025. GAAP operating margin was favorably impacted by a non-recurring impairment charge in the prior year, a non-recurring arbitration award in the prior year, and a recovery of assets held-for-sale.

​

Non-GAAP Earnings Results

​

Adjusted EPS increased to $1.93 per diluted share, compared to $1.92 last fiscal year. Adjusted operating income for fiscal 2026 increased 1% to $386.1 million, compared to $383.6 million for fiscal 2025. Adjusted operating margin was favorably impacted by profitability initiatives and the Exosome Diagnostics divestiture.

​

Segment Results

​

Management uses adjusted operating results to monitor and evaluate performance of the Company’s business segments, as highlighted below.

​

Protein Sciences Segment

​

The Company’s Protein Sciences segment is one of the world’s leading suppliers of specialized proteins such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biopharma and academic research communities. Additionally, the segment provides an array of platforms essential in various areas of protein analysis. The

Protein Sciences segment’s fourth quarter fiscal 2026 net sales were $231.2 million, an increase of 2% from $226.5 million in the fourth quarter of fiscal 2025. As of December 31, 2023, a business within the Protein Sciences segment met the criteria as held-for-sale; this held-for-sale business has been excluded from the segment’s operating results for both periods presented. Organic revenue increased 1% for the fourth quarter of fiscal 2026, with foreign currency exchange having a favorable impact of 1%. The Protein Sciences segment’s operating margin decreased to 42.0% in the fourth quarter of fiscal 2026 compared to 43.6% in the fourth quarter of fiscal 2025. The segment’s operating margin decreased primarily due to unfavorable volume and product mix.

​

Protein Sciences segment’s full year fiscal 2026 net sales were $874.6 million, an increase of 1% from $870.2 million for full year fiscal 2025. Organic revenue for the segment decreased 1% for the fiscal year, with foreign currency exchange having a favorable impact of

2%. Protein Sciences segment’s operating margin was 41.1% in fiscal 2026 compared to 42.6% in fiscal 2025. The segment’s operating margin was impacted by unfavorable volume and product mix.

​

Diagnostics and Spatial Biology Segment

​... (truncated) products, carrier screening and oncology kits. The Diagnostics and Spatial Biology segment also provides blood chemistry and blood gas quality controls, hematology instrument controls, immunoassays and other bulk and custom reagents for the in vitro diagnostic market.

The Diagnostics and Spatial Biology segment’s fourth quarter fiscal 2026 net sales remained flat at $90.1 million, as compared to $89.7 million in the fourth quarter of fiscal 2025. As of June 30, 2025, a business within the Diagnostics and Spatial Biology segment met the criteria as held-for-sale; this held-for-sale business has been excluded from the segment’s fiscal 2026 operating results. Organic revenue increased 8% for the fourth quarter of fiscal 2026, with foreign exchange not having a material impact. The held-for-sale business had an unfavorable impact of 8%. The Diagnostics and Spatial Biology segment’s operating margin increased to 11.2% in the fourth quarter of fiscal 2026 compared to 6.0% in the fourth quarter of fiscal 2025.

The segment’s operating margin was favorably impacted by the Exosome Diagnostics divestiture, favorable volume growth, and ongoing profitability initiatives.

​

The Diagnostics and Spatial Biology segment’s full year fiscal 2026 net sales were $336.4 million, a decrease of 3% from $346.3 million for the full year fiscal 2025. Organic growth for the segment was 4%, with foreign currency exchange having a favorable impact of 1%. A business held-for-sale had an unfavorable impact of 8%. The Diagnostics and Spatial Biology segment’s operating margin was 11.2% in fiscal 2026 compared to 6.2% in fiscal 2025. The segment’s operating margin was impacted by the divestiture of Exosome Diagnostics, favorable volume growth, and ongoing profitability initiatives.

​

​

About Bio-Techne

​

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high-quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer-focused brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision-making. Bio-Techne operates in 34 locations worldwide and employs approximately 3,000 people. In fiscal year 2026, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories. For more information on Bio-Techne and its brands, please visit www.bio-techne.com or follow the company on social media at

LinkedIn,

X, or

YouTube.

​

Forward Looking Statements:

​

Financial statements

Income Statement

Quarter Ended — (Unaudited)

Quarter Ended – June 30, – 2026Quarter Ended – June 30, – 2025Year Ended – June 30, – 2026Year Ended – June 30, – 2025
Net sales321,191316,9641,215,0391,219,635
Cost of sales109,797118,152415,968429,363
Gross margin211,394198,812799,071790,272
Operating expenses:Selling, general and administrative113,172196,640452,415588,521
Operating expenses:Research and development23,94526,03294,76699,496
Operating expenses:Total operating expenses137,117222,672547,181688,017
Operating expenses:Operating income74,277-23,860251,890102,255
Operating expenses:Other income (expense)-3,5961,001-11,210-3,792
Operating expenses:Earnings before income taxes70,681-22,859240,68098,463
Operating expenses:Income taxes16,059-5,18258,81825,063
Operating expenses:Net earnings54,622-17,677181,86273,400
Earnings per share:Basic0.35-0.111.170.47
Earnings per share:Diluted0.35-0.111.160.46
Weighted average common shares outstanding:Basic156,090154,913155,963157,521
Weighted average common shares outstanding:Diluted157,025155,757157,009159,717

Income Statement

Quarter Ended — (Unaudited)

Quarter Ended – June 30, – 2026Quarter Ended – June 30, – 2025Year Ended – June 30, – 2026Year Ended – June 30, – 2025
Total consolidated net sales321,191316,9641,215,0391,219,635
Business held-for-sale(1)5,4394,152
Revenue from recurring operations321,191316,9641,209,6001,215,483
Gross margin - GAAP211,394198,812799,071790,272
Gross margin percentage - GAAP65.8%62.765.8%64.8
Identified adjustments:Costs recognized upon sale of acquired inventory$—197$—751
Identified adjustments:Amortization of intangibles9,42210,56937,79944,035
Identified adjustments:Stock-based compensation, inclusive of employer taxes2822881,5341,298
Identified adjustments:Restructuring and restructuring-related costs1,04912,1415,80520,094
Identified adjustments:Impact of business held-for-sale(1)-2,581-147
Identified adjustments:Adjusted gross margin222,147222,007841,628856,303
Identified adjustments:Adjusted gross margin percentage(2)69.2%7069.6%70.4

Income Statement

Quarter Ended — (Unaudited)

Quarter Ended – June 30, – 2026Quarter Ended – June 30, – 2025Year Ended – June 30, – 2026Year Ended – June 30, – 2025
Net earnings54,622-17,677181,86273,400
Net interest expense (income)7501,5935,4054,623
Depreciation and amortization24,16927,11197,359109,903
Income taxes16,059-5,18258,81825,063
EBITDA95,6005,845343,444212,989
Amortization of Wilson Wolf intangible assets2,4902,4909,9599,959
Acquisition related expenses and other1,7824,0108,57013,489
Certain litigation charges1431,2205,51341,827
Stock-based compensation, inclusive of employer taxes5,3754,65342,63742,158
Restructuring and restructuring-related costs6,85813,20521,05928,231
Investment loss and other non-operating loss3,6955,009
Impairment (Recovery) of assets held-for-sale84,157-6,78980,503
Impact of business held-for-sale(1)2,573479
Adjusted EBITDA115,943115,580431,975429,635

Income Statement

Quarter Ended — (Unaudited)

Quarter Ended – June 30, – 2026Quarter Ended – June 30, – 2025Year Ended – June 30, – 2026Year Ended – June 30, – 2025
Net earnings before taxes - GAAP70,681-22,859240,68098,463
Identified adjustments:Amortization of intangibles15,07018,18561,18175,321
Identified adjustments:Amortization of Wilson Wolf intangible assets2,4902,4909,9599,959
Identified adjustments:Acquisition related expenses and other1,7824,0108,57013,489
Identified adjustments:Certain litigation charges1431,2205,51341,827
Identified adjustments:Stock-based compensation, inclusive of employer taxes5,3754,65342,63742,158
Identified adjustments:Restructuring and restructuring-related costs6,85813,20521,05928,231
Identified adjustments:Investment loss and other non-operating loss3,6955,009
Identified adjustments:Impairment (Recovery) of assets held-for-sale84,157-6,78980,503
Identified adjustments:Impact of business held-for-sale(1)2,573479
Identified adjustments:Net earnings before taxes - Adjusted106,094105,061390,392390,430
Identified adjustments:Non-GAAP tax rate22.3%21.5%22.3%21.5%
Identified adjustments:Non-GAAP tax expense23,65822,58987,05783,973
Identified adjustments:Non-GAAP adjusted net earnings82,43682,472303,335306,457
Identified adjustments:Earnings per share - diluted - Adjusted0.520.531.931.92

Income Statement

Quarter Ended — (Unaudited)

Quarter Ended – June 30, – 2026Quarter Ended – June 30, – 2025Year Ended – June 30, – 2026Year Ended – June 30, – 2025
Protein Sciences segment operating income97,07398,790359,401370,353
Diagnostics and Spatial Biology segment operating income10,0695,38437,69821,324
Segment operating income107,142104,174397,099391,677
Corporate general, selling, and administrative-3,783-2,847-11,049-8,088
Adjusted operating income103,359101,327386,050383,589
Amortization of intangibles-15,070-18,185-61,181-75,321
Acquisition related expenses and other-1,636-3,767-7,986-12,815
Certain litigation charges-143-1,220-5,513-41,827

Balance Sheet

(Unaudited)

June 30, – 2026June 30, – 2025
ASSETSCash and equivalents264,712162,186
ASSETSAccounts receivable, net216,585206,876
ASSETSInventories195,744189,446
ASSETSCurrent assets held-for-sale12,332
ASSETSOther current assets67,36037,460
ASSETSTotal current assets744,401608,300
ASSETSProperty and equipment, net231,836245,719
ASSETSRight of use assets67,33373,399
ASSETSGoodwill and intangible assets, net1,278,8201,346,534
ASSETSOther assets264,336283,916
ASSETSTotal assets2,586,7262,557,868
LIABILITIES AND STOCKHOLDERS' EQUITYAccounts payable and accrued expenses105,075116,765
LIABILITIES AND STOCKHOLDERS' EQUITYContract liabilities36,07232,571
LIABILITIES AND STOCKHOLDERS' EQUITYIncome taxes payable3,59310,770
LIABILITIES AND STOCKHOLDERS' EQUITYOperating lease liabilities - current14,93514,098
LIABILITIES AND STOCKHOLDERS' EQUITYOther current liabilities4,0251,645
LIABILITIES AND STOCKHOLDERS' EQUITYTotal current liabilities163,700175,849
LIABILITIES AND STOCKHOLDERS' EQUITYDeferred income taxes19,3086,169
LIABILITIES AND STOCKHOLDERS' EQUITYLong-term debt obligations200,000346,000
LIABILITIES AND STOCKHOLDERS' EQUITYOperating lease liabilities74,15283,960
LIABILITIES AND STOCKHOLDERS' EQUITYOther long-term liabilities21,34527,082
LIABILITIES AND STOCKHOLDERS' EQUITYStockholders' equity2,108,2211,918,808
LIABILITIES AND STOCKHOLDERS' EQUITYTotal liabilities and stockholders' equity2,586,7262,557,868

Cash Flow

(Unaudited)

Year Ended – June 30, – 2026Year Ended – June 30, – 2025
CASH FLOWS FROM OPERATING ACTIVITIESNet earnings181,86273,400
Adjustments to reconcile net earnings to net cash provided by operating activitiesDepreciation and amortization97,359109,903
Adjustments to reconcile net earnings to net cash provided by operating activitiesCosts recognized on sale of acquired inventory751
Adjustments to reconcile net earnings to net cash provided by operating activitiesDeferred income taxes13,196-51,107
Adjustments to reconcile net earnings to net cash provided by operating activitiesStock-based compensation expense41,36540,833
Adjustments to reconcile net earnings to net cash provided by operating activities(Gain) Loss on equity method investment-887-938
Adjustments to reconcile net earnings to net cash provided by operating activitiesAsset impairment restructuring3,91421,312
Adjustments to reconcile net earnings to net cash provided by operating activitiesRecovery of assets held-for-sale-6,78980,503
Adjustments to reconcile net earnings to net cash provided by operating activitiesOther operating activities-37,94712,899
Adjustments to reconcile net earnings to net cash provided by operating activitiesNet cash provided by (used in) operating activities292,073287,556
CASH FLOWS FROM INVESTING ACTIVITIESProceeds from sale of available-for-sale investments1,085
CASH FLOWS FROM INVESTING ACTIVITIESAdditions to property and equipment-28,850-31,006
CASH FLOWS FROM INVESTING ACTIVITIESDistributions from Wilson Wolf6,0437,291
CASH FLOWS FROM INVESTING ACTIVITIESInvestment in Spear Bio-15,000
CASH FLOWS FROM INVESTING ACTIVITIESProceeds from sale of assets held-for-sale4,6172,447
CASH FLOWS FROM INVESTING ACTIVITIESNet cash provided by (used in) investing activities-18,190-35,183
CASH FLOWS FROM FINANCING ACTIVITIESCash dividends-49,916-50,391
CASH FLOWS FROM FINANCING ACTIVITIESProceeds from stock option exercises80,61851,739
CASH FLOWS FROM FINANCING ACTIVITIESLong-term debt activity, net-146,00027,000
CASH FLOWS FROM FINANCING ACTIVITIESRepurchases of common stock-41,675-275,731
CASH FLOWS FROM FINANCING ACTIVITIESTaxes paid on RSUs and net share settlements-12,141-6,522
CASH FLOWS FROM FINANCING ACTIVITIESNet cash provided by (used in) financing activities-169,114-253,905
CASH FLOWS FROM FINANCING ACTIVITIESEffect of exchange rate changes on cash and cash equivalents-2,24311,927
CASH FLOWS FROM FINANCING ACTIVITIESNet increase (decrease) in cash and cash equivalents102,52610,395
CASH FLOWS FROM FINANCING ACTIVITIESCash and cash equivalents at beginning of period162,186151,791
CASH FLOWS FROM FINANCING ACTIVITIESCash and cash equivalents at end of period264,712162,186
Full release

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements use words and variations of words, such as “will,” “plan,” “continue,” “believe,” “outlook,” “expect,” and “predict.” These statements are made as of the date of this press release, are based on current expectations of future events, and thus are inherently subject to a number of risks and uncertainties, many of which involve factors or circumstances beyond the Company’s control. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the Company’s expectations and projections. These risks, uncertainties, and other factors include, without limitation: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company’s customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

​

For additional information concerning these risks, uncertainties, and other factors, see the section titled “Risk Factors” in the Company’s most recent annual report on Form 10-K as filed with the Securities and Exchange Commission. We undertake and we expressly disclaim any obligation to update or revise any forward-looking statements due to new information, changed assumptions, or future events, except as required by law. Investors are cautioned not to place undue reliance on forward-looking statements.

​

Non-GAAP Financial Measures:

​

The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the U.S. (GAAP). This press release contains financial measures that have not been calculated in accordance with GAAP. These non-GAAP measures include:

​

​

These non-GAAP measures should not be considered in isolation or as a substitute for any measure derived in accordance with GAAP and may also be inconsistent with similar measures presented by other companies. Reconciliations of these measures to the applicable most closely comparable GAAP measures, and reasons for the Company’s use of these measures, are presented in the attached pages.

​

David.Clair@bio-techne.com

612-656-4416

​

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.